Comparative Pharmacology
Head-to-head clinical analysis: THEOLAIR SR versus XOPENEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOLAIR SR versus XOPENEX.
THEOLAIR-SR vs XOPENEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
Selective beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP levels.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
Nebulized solution: 0.63 mg or 1.25 mg 3 times daily every 6-8 hours; metered-dose inhaler: 2 inhalations (90 mcg per inhalation) 3 times daily every 6-8 hours.
None Documented
None Documented
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Terminal elimination half-life: 3.3-4.0 hours in adults. Clinically, twice-daily dosing is not recommended due to shorter half-life; every 4-6 hour dosing is standard for acute bronchodilation.
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Renal: 80-100% as unchanged drug and metabolites (approximately 60% as unchanged levalbuterol, 20% as inactive sulfate conjugate). Fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator